Equibles does not estimate personal net worth.
Get an email with a short summary when Maravai Lifesciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get MRVI alertsBernd Brust is recorded as Board Member at Maravai Lifesciences Holdings, Inc. (MRVI) since January 1, 2025 and CEO at Maravai Lifesciences Holdings, Inc. (MRVI). The newest filing on record that lists Bernd Brust as CEO and Board Member at Maravai Lifesciences Holdings, Inc. (MRVI) is dated April 24, 2026. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 9, 2025 that Bernd Brust was appointed member of the Board of Directors, effective June 9, 2025. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 9, 2025 that Bernd Brust was appointed Chief Executive Officer (CEO) and a member of the Board of Directors, effective June 9, 2025. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed June 9, 2025 that Bernd Brust was appointed member of the Board, effective June 8, 2025. Equibles holds 4 filed executive changes naming Bernd Brust; each is listed under recent activity with its source filing. The proxy statement of Maravai Lifesciences Holdings, Inc. reports total compensation of $10,129,708 for Bernd Brust in fiscal 2025, including a base salary of $388,863. Bernd Brust has spoken on 5 earnings calls across 1 company, most recently for Maravai Lifesciences Holdings, Inc. on August 6, 2026. Maravai Lifesciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Maravai Lifesciences Holdings, Inc. includes William "Trey" Martin, III (CEO and Board Member), William E. Martin III (CEO), William Martin (CEO) and 7 others.
“Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately.”
“Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately.”
“We are very pleased with our second quarter performance, which builds on the strong momentum we established in the first quarter. Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy.”
“We are very pleased with our first quarter performance, which represents a strong start to 2026 and builds on the momentum we exited with last year. The quarter results reflect solid execution across the business and reinforce our confidence in the trajectory we outlined on our call in February.”
“After assuming the CEO role last June and implementing the restructuring actions we announced last August, the management team and I were clear on our priorities.”
“Let's begin with a review of our third quarter performance on Slide 5. For Q3, we reported $41.6 million in total revenue with Biologic Safety Testing generating $16.3 million, growing at 7% and Nucleic Acid Products contributing $25.4 million, declining at 53% year-over-year.”
“I'd like to begin with my reasons for accepting the role as CEO and in this context, frame for investors the incredible opportunities I see ahead for the company.”
2025-01-01–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CEO, Board Member
2025-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Executive Officer | $388,863 | $10,129,708 |
